Quantcast

Latest Parkinson's disease Stories

2014-08-21 16:24:23

REHOVOT, Israel, August 21, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group. The company plans to use the funding to further the clinical and regulatory...

Premiere Of Universal Pictures "Man Of the Year" - Arrivals
2014-08-19 05:17:09

Rayshell Clapper for redOrbit.com - Your Universe Online On August 11, 2014, people were rocked by the news that Robin Williams had committed suicide by asphyxiation. He hung himself according to one CNN article. For many, the shock was too confusing. Williams helped the world through his stage performances, shows, and movies. He did charity work, entertained the troops, and spread laughter to many. His sudden suicide hurt many. A Huffington Post report included a written statement from...

parkinsons dopamine
2014-08-18 15:08:09

Lee-Ann Donegan, Penn Medicine Study Examined Patients Over First Two Years of Treatment New Penn Medicine research shows that neuropsychiatric symptoms such as depression, anxiety and fatigue are more common in newly diagnosed Parkinson’s disease (PD) patients compared to the general population. The study also found that initiation of dopamine replacement therapy, the most common treatment for PD, was associated with increasing frequency of impulse control disorders and excessive...

2014-08-12 08:31:15

NEW YORK, Aug. 12, 2014 /PRNewswire-USNewswire/ -- Research projects from five groups active in Parkinson's research comprise the 2014 first half (1H 2014) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program projects are presented directly to industry groups who may wish to invest in further development. By connecting industry leaders with those studies ripe for investment, the...

2014-08-05 16:27:31

GRAND RAPIDS, Mich., Aug. 5, 2014 /PRNewswire/ -- Van Andel Research Institute (VARI) is scheduled to host Rallying to the Challenge, a meeting which highlights the many ways people with Parkinson's disease can impact the clinical trial process and accelerate access to new Parkinson's disease treatments. http://photos.prnewswire.com/prnvar/20140417/76339 The meeting will take place during the third annual Grand Challenges in Parkinson's Disease symposium, one of the most...

2014-08-05 12:32:03

NEW YORK, Aug. 5, 2014 /PRNewswire-USNewswire/ -- Researchers need to know the genetic profiles of their study participants to understand more about how certain mutations manifest disease. But do the participants have to know? A group of 35 Parkinson's disease (PD) researchers published today in Genetics of Medicine the different answers to that question among sites investigating mutations in the LRRK2 gene, the greatest known genetic contributor to PD. Investigators from The Michael...

2014-08-04 23:09:13

FPRT Bio works closely with academic leaders and research organizations to advance the use of XPro1595 in the treatment of Parkinson’s disease. Dallas, Texas (PRWEB) August 04, 2014 FPRT Bio, a privately held clinical stage biopharmaceutical company, is developing XPro1595, a novel second generation inhibitor of soluble TNF, for the treatment of neurodegenerative diseases including ALS, MS, Parkinson’s and Alzheimer’s diseases. FPRT Bio works closely with academic partners and...

2014-08-04 08:57:44

MPG Max Planck researchers show that two products of the gene DJ-1 can increase the survival of neurons Parkinson’s disease affects neurons in the Substantia nigra brain region – their mitochondrial activity ceases and the cells die. Researchers at the Max Planck Institute of Molecular Cell Biology and Genetics show that supplying D-lactate or glycolate, two products of the gene DJ-1, can stop and even counteract this process: Adding the substances to cultured HeLa cells and to...

2014-08-04 08:27:58

REHOVOT, Israel, August 4, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd. today announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson's disease, eligible for a European Union marketing authorization application procedure ("centralized procedure"). According to EMA guidelines, the EMA can allow products for which the centralized...

2014-07-31 12:29:21

AFFiRiS AG presents Phase I data on a first-of-its-kind treatment with support from The Michael J. Fox Foundation NEW YORK and VIENNA, July 31, 2014 /PRNewswire/ -- AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson's disease. PD01A is the first therapy against the protein alpha-synuclein, a promising Parkinson's drug target, to enter clinical testing. The Michael J. Fox...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related